Related Experiment Video
Updated: Apr 16, 2026
12:16
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
Published on: March 13, 2013
21.9K
CD133 is a selective marker of CRC?
1Unit of Surgery and Organ Transplantation University Hospital of Parma, Parma, Italia - paolo.delrio@unipr.it.
Minerva Chirurgica
|April 16, 2013
Summary
This study investigated CD133, a marker for cancer stem cells, in colorectal cancer patients. High CD133 expression was observed in most patients, suggesting its potential role in tumor progression and chemoresistance.
Area of Science:
- Oncology
- Cancer Stem Cell Biology
- Molecular Pathology
Background:
- Colorectal cancer (CRC) remains a significant health concern globally.
- Cancer stem cells (CSCs) are implicated in tumor initiation, progression, and therapeutic resistance.
- CD133 is a cell surface glycoprotein investigated as a potential CSC marker.
Purpose of the Study:
- To evaluate the expression of CD133 as a marker of CSCs in CRC.
- To assess CD133 as an independent prognostic factor for patient survival.
- To investigate the correlation between CD133 expression and resistance to chemotherapy.
Main Methods:
- Immunohistochemical analysis using the monoclonal antibody CD133/1.
- Study included 26 patients with colorectal cancer undergoing curative surgery.
- Follow-up period of 5 years to assess survival outcomes.
Main Results:
- CD133 expression was detected in 96.5% of the evaluated CRC patients (25 out of 26).
- CD133 positivity intensity varied and was related to positive cell pull.
- No significant association was found between CD133 positivity and other clinic-pathological characteristics.
Conclusions:
- The study confirms a high prevalence of CD133 in colorectal tumor epithelium, aligning with existing research.
- Further prospective, randomized studies with larger cohorts are warranted.
- The precise role of CD133 and other potential CSC markers in CRC requires further investigation to validate their clinical utility.
